论文部分内容阅读
目的探究营养风险与支持应用于胃肠肿瘤外科的临床价值。方法对我院接收的105例胃肠肿瘤患者进行研究,对其进行营养风险筛查与评估,并采用NRS2002将NRS评分<3分45例患者作为阴性组对象,NRS评分≥3分60例患者作为阳性组对象,而给予肠外营养支持对象作为实验组,未予以营养支持对象为对照组,各30例。结果≥50岁患者≥3分NRS几率(66.10%)表高于<50岁患者(43.48%),且P<0.05,差异具有统计学意义。不同BMI患者在NRS评分均无统计学差异,P>0.05。治疗前,各组患者HB、PA与血清ALB均无统计学差异,P>0.05;营养支持后,NRS阳性实验组患者各项指标情况明显优于对照组,且P<0.05,差异具有统计学意义。结论胃肠肿瘤患者发生营养风险几率较高,化疗治疗期间应适时给予营养支持,以提高患者耐受性与抵抗力。
Objective To explore the clinical value of nutrition risk and support in the surgical treatment of gastrointestinal tumors. Methods A total of 105 gastrointestinal tumors received in our hospital were studied and their nutritional risks were screened and evaluated. The NRS score was used as the negative group with NRS score <3 points and 45 cases, NRS score ≥ 3 points and 60 cases As a positive group, while parenteral nutrition support object as experimental group, no nutritional support for the control group, 30 cases each. Results The ≥3 score of NRS in patients ≥50 years old was higher than that in patients <50 years old (43.48%) (P <0.05). The difference was statistically significant. There was no significant difference in NRS between different BMI patients, P> 0.05. Before treatment, there was no significant difference between HB, PA and serum ALB in all groups (P> 0.05). After nutritional support, the indexes of patients in NRS positive group were significantly better than those in control group, P <0.05, the difference was statistically significant significance. Conclusion Patients with gastrointestinal tumors have a higher risk of nutritional risk. Nutritional support should be given timely to improve patient tolerance and resistance.